ANI Pharmaceuticals Inc. (ANIP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ANI Pharmaceuticals Inc. (ANIP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

54.22

0.29 (0.54%)

At close: Jan 14, 2025, 3:59 PM

54.16

-0.11%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	31.71
Market Cap	1.14B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.47
PE Ratio (ttm)	-115.36
Forward PE	n/a
Analyst	Buy

Ask	56.57
Volume	97,135
Avg. Volume (20D)	258,973
Open	54.11
Previous Close	53.93
Day's Range	53.35 - 54.48
52-Week Range	52.50 - 70.81
Beta	undefined

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development a...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 5, 2000

Employees 642

Stock Exchange NASDAQ

Ticker Symbol ANIP

Website https://www.anipharmaceuticals.com

Analyst Forecast

According to 7 analyst ratings, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is $78.5, which is an increase of 44.78% from the latest price.

Buy 85.71%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Next Earnings Release

ANI Pharmaceuticals Inc. is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of $175.12M, reflecting a 33.02% YoY growth and earnings per share of 0.31, making a -69.00% decrease YoY.

Why Price Moved

5 months ago · Source

-9.92%

ANI Pharmaceuticals shares are trading lower after... Unlock content with Pro Subscription

5 months ago · Source

+6.98%

ANI Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 guidance.

News

1 week ago · zacks.com

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

2 weeks ago · zacks.com

All You Need to Know About ANI (ANIP) Rating Upgrade to Buy

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago · zacks.com

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

1 month ago · zacks.com

Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect?

The consensus price target hints at a 31.3% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revi...

1 month ago · zacks.com

ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

2 months ago · seekingalpha.com

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz ...

2 months ago · zacks.com

Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

2 months ago · zacks.com

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago.

2 months ago · zacks.com

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

3 months ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

3 months ago · zacks.com

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.